Barinthus Biotherapeutics/$BRNS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Barinthus Biotherapeutics
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
Ticker
$BRNS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
105
Website
BRNS Metrics
BasicAdvanced
$60M
-
-$1.64
-0.80
-
Price and volume
Market cap
$60M
Beta
-0.8
52-week high
$2.92
52-week low
$0.64
Average daily volume
2.6M
Financial strength
Current ratio
9.175
Quick ratio
8.598
Long term debt to equity
8.616
Total debt to equity
10.311
Interest coverage (TTM)
-920.93%
Profitability
EBITDA (TTM)
-46.526
Gross margin (TTM)
107.35%
Net profit margin (TTM)
-435.79%
Operating margin (TTM)
-332.22%
Effective tax rate (TTM)
0.04%
Revenue per employee (TTM)
$140,000
Management effectiveness
Return on assets (TTM)
-18.20%
Return on equity (TTM)
-45.42%
Valuation
Price to revenue (TTM)
3.927
Price to book
0.52
Price to tangible book (TTM)
0.63
Price to free cash flow (TTM)
-1.803
Free cash flow yield (TTM)
-55.47%
Free cash flow per share (TTM)
-0.821
Growth
Revenue change (TTM)
4,381.74%
Earnings per share change (TTM)
-10.34%
3-year revenue growth (CAGR)
-0.23%
3-year earnings per share growth (CAGR)
18.19%
What the Analysts think about BRNS
Analyst ratings (Buy, Hold, Sell) for Barinthus Biotherapeutics stock.
BRNS Financial Performance
Revenues and expenses
BRNS Earnings Performance
Company profitability
BRNS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Barinthus Biotherapeutics stock?
Barinthus Biotherapeutics (BRNS) has a market cap of $60M as of August 01, 2025.
What is the P/E ratio for Barinthus Biotherapeutics stock?
The price to earnings (P/E) ratio for Barinthus Biotherapeutics (BRNS) stock is 0 as of August 01, 2025.
Does Barinthus Biotherapeutics stock pay dividends?
No, Barinthus Biotherapeutics (BRNS) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Barinthus Biotherapeutics dividend payment date?
Barinthus Biotherapeutics (BRNS) stock does not pay dividends to its shareholders.
What is the beta indicator for Barinthus Biotherapeutics?
Barinthus Biotherapeutics (BRNS) has a beta rating of -0.8. This means that it has an inverse relation to market volatility.